Novo Nordisk’s Amycretin: A New Contender In Obesity Treatment
Novo Nordisk, a leading pharmaceutical company, has presented new data on its next-generation obesity drug, amycretin, which has sparked investor optimism and raised expectations within the weight-loss drug market. According to early-stage trial results, amycretin demonstrated a 22% weight loss over 36 weeks, a significant achievement compared to the 2% weight loss seen in the…









